during the year 2020 we announced several new agreements with german shis such as tk and dak gesundheit and others as well as the first german private health insurer ( “ phi ” ) that have chosen to enter into an agreement that outlines the process of obtaining a device for eligible insured patient . we are currently working with several additional shis and phis on securing a formal operating contract that will establish the process of obtaining a rewalk personal 6.0 device for their beneficiaries within their system . during the second quarter of 2020 we finalized and moved to implement two separate agreements to distribute additional product lines in the u.s. market . the company will be the exclusive distributor of the meditouch tutor movement biofeedback systems in the united states and will also have distribution rights for the myolyn myocycle fes cycles to u.s. rehabilitation clinics and personal sales through the va hospitals . these new products will improve our product offering to clinics as well as patients within the va as they both have similar clinician and patient profile . we have incurred net losses and negative cash flow from operations since inception and anticipate this to continue in the near term . we will continue to evaluate spending while continuing to focus resources on activities to commercialize the restore device for stroke patients , achieving additional commercial reimbursement coverage decisions for our rewalk personal device , continued research and development activities related mainly to our product line maintenance as well as our soft exo-suit design and activities related to our fda 522 postmarket study . for information on the effects to our company from the ongoing covid-19 pandemic , see “ part i , item 1. business—evolving covid-19 pandemic . ” 62 components of our statements of operations revenues we currently rely , and in the future will rely , on sales and rentals of our rewalk personal 6.0 device , our restore device , additional devices such as myocycle and meditouch which we are distributing ( “ distributed products ” ) and related service contracts and extended warranties for our revenue . our revenue is generated from a combination of third-party payors , institutions , and self-payors , including private and government employers . payments for our products by third party payors have been made primarily through case-by-case determinations . third-party payors include , without limitation , private insurance plans and managed care programs , government programs including the va , and worker 's compensation payments . we expect that third-party payors will be an increasingly important source of revenue in the future as well as clinics that will be interested in the restore device . in december 2015 , the va issued a national policy for the evaluation , training and procurement of rewalk personal exoskeleton systems for all qualifying veterans across the united states . the va policy is the first national coverage policy in the united states for qualifying individuals who have suffered spinal cord injury . all of our rewalk personal and rewalk rehabilitation systems sold until the end of 2017 were covered by a two-year warranty from the date of purchase , which is included in the purchase price . we offer customers the ability to purchase , any time during the initial warranty period , an extended warranty for up to three additional years . both warranties cover all elements of the systems , including the batteries , other than normal wear and tear . in the beginning of 2018 , we updated our service policy for new devices sold to include a five-year warranty . our restore device is sold with a two-year warranty . the distributed products warranty ranges between one year to ten years depending on the specific product and part . cost of revenues and gross profit cost of revenue consists primarily of systems purchased from our outsourced manufacturer , sanmina , salaries , personnel costs including non-cash share-based compensation , associated with manufacturing and inventory management , training and inspection , warranty and service costs , shipping and handling and manufacturing startup and transition costs . cost of revenues also includes royalties and expenses related to royalty-bearing research and development grants and sales and marketing grants . our gross profit and gross margin as a percentage of sales is influenced by a number of factors , including primarily the volume and price of our products sold and fluctuations in our cost of revenues . we expect gross profit as a percentage of sales will improve in the future as we increase our sales volumes and decrease the product manufacturing costs . operating expenses research and development expenses , net research and development expenses , net consist primarily of salaries , related personnel costs including share-based compensation , supplies , materials and consulting expenses related to product design and development , clinical studies , regulatory submissions , patent costs , sponsored research costs and other expenses related to our product development and research programs . we expense all research and development expenses as they are incurred . research and development expenses are presented net of the amount of any grants we receive for research and development in the period in which we receive the grant . we previously received grants and other funding from the bird foundation and the israel innovation authority , or “ iia ” ( formerly known as the office of the chief scientist ) . certain of those grants require us to pay royalties on sales of rewalk systems , which are recorded as cost of revenues . we may receive additional funding from these entities or others in the future . see “ grants and other funding ” below . story_separator_special_tag we selected the black-scholes-merton option pricing model as the most appropriate method for determining the estimated fair value of options . the resulting cost of an equity incentive award is recognized as an expense over the requisite service period of the award , which is usually the vesting period . we recognize compensation expense over the vesting period using the straight-line method and classify these amounts in the consolidated financial statements based on the department to which the related employee reports . 69 the determination of the grant date fair value of options using the black-scholes-merton option pricing model is affected by estimates and assumptions regarding a number of complex and subjective variables . these variables include the expected volatility of our share price over the expected term of the options , share option exercise and cancellation behaviors , risk-free interest rates and expected dividends , which are estimated as follows : risk-free interest rate . the risk-free interest rate is based on the yield from u.s. treasury zero-coupon bonds with a term equivalent to the contractual life of the options . dividend yield . we have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future . consequently , we used an expected dividend yield of zero . expected volatility . we estimated the expected share price volatility for our ordinary shares by considering the historic price volatility for industry peers based on price observations over a period equivalent to the expected term of the share option grants . industry peers consist of public companies in the medical device and healthcare industries . we intend to continue to consistently apply this process using the same or similar industry peers until a sufficient amount of historical information regarding the volatility of our ordinary share price becomes available , or unless circumstances change such that the identified companies are no longer similar to us , in which case , more suitable companies whose share prices are publicly available would be utilized in the calculation . expected term . the expected term of options granted represents the period of time that options granted are expected to be outstanding and is determined based on the simplified method in accordance with asc no . 718-10-s99-1 ( sab no . 110 ) , as adequate historical experience is not available to provide a reasonable estimate . asc no . 718 requires forfeitures to be estimated at the time of grant and revised , if necessary , in subsequent periods if actual forfeitures differ from those estimates . the fair value of rsus granted is determined based on the price of the company 's ordinary shares on the date of grant . income taxes as part of the process of preparing our consolidated financial statements , we are required to estimate our taxes in each of the jurisdictions in which we operate . we account for income taxes in accordance with asc topic 740 , “ income taxes , ” or asc topic 740. asc topic 740 prescribes the use of an asset and liability method whereby deferred tax asset and liability account balances are determined based on the difference between book value and the tax bases of assets and liabilities and carryforward tax losses . deferred taxes are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse . we exercise judgment and provide a valuation allowance , if necessary , to reduce deferred tax assets to their estimated realizable value if it is more likely than not that some portion or all of the deferred tax asset will not be realized . we have established a full valuation allowance with respect to our deferred tax assets . asu 2015-17 , “ balance sheet classification of deferred taxes ” provides presentation requirements to classify deferred tax assets and liabilities , along with any related valuation allowance , are classified as non-current on the balance sheet . we account for uncertain tax positions in accordance with asc 740 and recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities , based on the technical merits of the position . the tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50 % likelihood of being realized upon ultimate settlement . accordingly , we report a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return . we recognize interest and penalties , if any , related to unrecognized tax benefits in tax expense . recently issued and adopted accounting pronouncements a discussion of recent accounting pronouncements is included in note 2v , new accounting pronouncements to our consolidated financial statements in this annual report . 70 liquidity and capital resources sources of liquidity and outlook since inception , we have funded our operations primarily through the sale of our equity securities and convertible notes to investors in private placements , the sale of our equity securities in public offerings , cash exercises of outstanding warrants and the incurrence of bank debt . for the full year ended december 31 , 2020 , the company incurred a consolidated net loss of $ 13 million and has an accumulated deficit in the total amount of $ 181.4 million . our cash and cash equivalent on december 31 , 2020 , totaled $ 20.3 million , and in subsequent warrants exercise transactions the company received a total of an additional $ 13.2 million in the beginning of 2021. the company 's negative operating cash flow for the full year ended december 31 , 2020 , was $ 12.6 million . the company has sufficient funds to support its operation for more than 12

cash flows replace_table_token_10_th year ended december 31 , 2020 to year ended december 31 , 2019 net cash used in operating activities net cash used in operating activities decreased by $ 2.2 million in 2020 compared to 2019 mainly due to our reduction in our net loss . net cash used in investing activities net cash used in investing activities increased from $ 22 thousand in 2019 to $ 73 thousand in 2020 , primarily as a result of increased use of cash for the purchase of property and equipment . net cash provided by financing activities we generated $ 16.7 million from financing activities in 2020 compared to $ 21.5 million in 2019. our fundraising activities remained generally flat with $ 23.3 million raised in 2020 and 2019 and the overall decrease is due to our kreos loan repayment which was higher by $ 5.2 million in 2020. year ended december 31 , 2019 compared to year ended december 31 , 2018 a discussion of changes in our cash flows in 2019 compared to 2018 has been omitted from this annual report on form 10-k , but may be found in “ item 7. management 's discussion and analysis of financial condition and results of operations ” of our form 10-k for the fiscal year ended december 30 , 2019 , filed with the sec on february 20 , 2020 , which is available free of charge on the secs website at www.sec.go vand at www.rewalk.com , and is incorporated by reference herein .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows replace_table_token_10_th year ended december 31 , 2020 to year ended december 31 , 2019 net cash used in operating activities net cash used in operating activities decreased by $ 2.2 million in 2020 compared to 2019 mainly due to our reduction in our net loss . net cash used in investing activities net cash used in investing activities increased from $ 22 thousand in 2019 to $ 73 thousand in 2020 , primarily as a result of increased use of cash for the purchase of property and equipment . net cash provided by financing activities we generated $ 16.7 million from financing activities in 2020 compared to $ 21.5 million in 2019. our fundraising activities remained generally flat with $ 23.3 million raised in 2020 and 2019 and the overall decrease is due to our kreos loan repayment which was higher by $ 5.2 million in 2020. year ended december 31 , 2019 compared to year ended december 31 , 2018 a discussion of changes in our cash flows in 2019 compared to 2018 has been omitted from this annual report on form 10-k , but may be found in “ item 7. management 's discussion and analysis of financial condition and results of operations ” of our form 10-k for the fiscal year ended december 30 , 2019 , filed with the sec on february 20 , 2020 , which is available free of charge on the secs website at www.sec.go vand at www.rewalk.com , and is incorporated by reference herein .
```    
 Suspicious Activity Report : during the year 2020 we announced several new agreements with german shis such as tk and dak gesundheit and others as well as the first german private health insurer ( “ phi ” ) that have chosen to enter into an agreement that outlines the process of obtaining a device for eligible insured patient . we are currently working with several additional shis and phis on securing a formal operating contract that will establish the process of obtaining a rewalk personal 6.0 device for their beneficiaries within their system . during the second quarter of 2020 we finalized and moved to implement two separate agreements to distribute additional product lines in the u.s. market . the company will be the exclusive distributor of the meditouch tutor movement biofeedback systems in the united states and will also have distribution rights for the myolyn myocycle fes cycles to u.s. rehabilitation clinics and personal sales through the va hospitals . these new products will improve our product offering to clinics as well as patients within the va as they both have similar clinician and patient profile . we have incurred net losses and negative cash flow from operations since inception and anticipate this to continue in the near term . we will continue to evaluate spending while continuing to focus resources on activities to commercialize the restore device for stroke patients , achieving additional commercial reimbursement coverage decisions for our rewalk personal device , continued research and development activities related mainly to our product line maintenance as well as our soft exo-suit design and activities related to our fda 522 postmarket study . for information on the effects to our company from the ongoing covid-19 pandemic , see “ part i , item 1. business—evolving covid-19 pandemic . ” 62 components of our statements of operations revenues we currently rely , and in the future will rely , on sales and rentals of our rewalk personal 6.0 device , our restore device , additional devices such as myocycle and meditouch which we are distributing ( “ distributed products ” ) and related service contracts and extended warranties for our revenue . our revenue is generated from a combination of third-party payors , institutions , and self-payors , including private and government employers . payments for our products by third party payors have been made primarily through case-by-case determinations . third-party payors include , without limitation , private insurance plans and managed care programs , government programs including the va , and worker 's compensation payments . we expect that third-party payors will be an increasingly important source of revenue in the future as well as clinics that will be interested in the restore device . in december 2015 , the va issued a national policy for the evaluation , training and procurement of rewalk personal exoskeleton systems for all qualifying veterans across the united states . the va policy is the first national coverage policy in the united states for qualifying individuals who have suffered spinal cord injury . all of our rewalk personal and rewalk rehabilitation systems sold until the end of 2017 were covered by a two-year warranty from the date of purchase , which is included in the purchase price . we offer customers the ability to purchase , any time during the initial warranty period , an extended warranty for up to three additional years . both warranties cover all elements of the systems , including the batteries , other than normal wear and tear . in the beginning of 2018 , we updated our service policy for new devices sold to include a five-year warranty . our restore device is sold with a two-year warranty . the distributed products warranty ranges between one year to ten years depending on the specific product and part . cost of revenues and gross profit cost of revenue consists primarily of systems purchased from our outsourced manufacturer , sanmina , salaries , personnel costs including non-cash share-based compensation , associated with manufacturing and inventory management , training and inspection , warranty and service costs , shipping and handling and manufacturing startup and transition costs . cost of revenues also includes royalties and expenses related to royalty-bearing research and development grants and sales and marketing grants . our gross profit and gross margin as a percentage of sales is influenced by a number of factors , including primarily the volume and price of our products sold and fluctuations in our cost of revenues . we expect gross profit as a percentage of sales will improve in the future as we increase our sales volumes and decrease the product manufacturing costs . operating expenses research and development expenses , net research and development expenses , net consist primarily of salaries , related personnel costs including share-based compensation , supplies , materials and consulting expenses related to product design and development , clinical studies , regulatory submissions , patent costs , sponsored research costs and other expenses related to our product development and research programs . we expense all research and development expenses as they are incurred . research and development expenses are presented net of the amount of any grants we receive for research and development in the period in which we receive the grant . we previously received grants and other funding from the bird foundation and the israel innovation authority , or “ iia ” ( formerly known as the office of the chief scientist ) . certain of those grants require us to pay royalties on sales of rewalk systems , which are recorded as cost of revenues . we may receive additional funding from these entities or others in the future . see “ grants and other funding ” below . story_separator_special_tag we selected the black-scholes-merton option pricing model as the most appropriate method for determining the estimated fair value of options . the resulting cost of an equity incentive award is recognized as an expense over the requisite service period of the award , which is usually the vesting period . we recognize compensation expense over the vesting period using the straight-line method and classify these amounts in the consolidated financial statements based on the department to which the related employee reports . 69 the determination of the grant date fair value of options using the black-scholes-merton option pricing model is affected by estimates and assumptions regarding a number of complex and subjective variables . these variables include the expected volatility of our share price over the expected term of the options , share option exercise and cancellation behaviors , risk-free interest rates and expected dividends , which are estimated as follows : risk-free interest rate . the risk-free interest rate is based on the yield from u.s. treasury zero-coupon bonds with a term equivalent to the contractual life of the options . dividend yield . we have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future . consequently , we used an expected dividend yield of zero . expected volatility . we estimated the expected share price volatility for our ordinary shares by considering the historic price volatility for industry peers based on price observations over a period equivalent to the expected term of the share option grants . industry peers consist of public companies in the medical device and healthcare industries . we intend to continue to consistently apply this process using the same or similar industry peers until a sufficient amount of historical information regarding the volatility of our ordinary share price becomes available , or unless circumstances change such that the identified companies are no longer similar to us , in which case , more suitable companies whose share prices are publicly available would be utilized in the calculation . expected term . the expected term of options granted represents the period of time that options granted are expected to be outstanding and is determined based on the simplified method in accordance with asc no . 718-10-s99-1 ( sab no . 110 ) , as adequate historical experience is not available to provide a reasonable estimate . asc no . 718 requires forfeitures to be estimated at the time of grant and revised , if necessary , in subsequent periods if actual forfeitures differ from those estimates . the fair value of rsus granted is determined based on the price of the company 's ordinary shares on the date of grant . income taxes as part of the process of preparing our consolidated financial statements , we are required to estimate our taxes in each of the jurisdictions in which we operate . we account for income taxes in accordance with asc topic 740 , “ income taxes , ” or asc topic 740. asc topic 740 prescribes the use of an asset and liability method whereby deferred tax asset and liability account balances are determined based on the difference between book value and the tax bases of assets and liabilities and carryforward tax losses . deferred taxes are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse . we exercise judgment and provide a valuation allowance , if necessary , to reduce deferred tax assets to their estimated realizable value if it is more likely than not that some portion or all of the deferred tax asset will not be realized . we have established a full valuation allowance with respect to our deferred tax assets . asu 2015-17 , “ balance sheet classification of deferred taxes ” provides presentation requirements to classify deferred tax assets and liabilities , along with any related valuation allowance , are classified as non-current on the balance sheet . we account for uncertain tax positions in accordance with asc 740 and recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities , based on the technical merits of the position . the tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50 % likelihood of being realized upon ultimate settlement . accordingly , we report a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return . we recognize interest and penalties , if any , related to unrecognized tax benefits in tax expense . recently issued and adopted accounting pronouncements a discussion of recent accounting pronouncements is included in note 2v , new accounting pronouncements to our consolidated financial statements in this annual report . 70 liquidity and capital resources sources of liquidity and outlook since inception , we have funded our operations primarily through the sale of our equity securities and convertible notes to investors in private placements , the sale of our equity securities in public offerings , cash exercises of outstanding warrants and the incurrence of bank debt . for the full year ended december 31 , 2020 , the company incurred a consolidated net loss of $ 13 million and has an accumulated deficit in the total amount of $ 181.4 million . our cash and cash equivalent on december 31 , 2020 , totaled $ 20.3 million , and in subsequent warrants exercise transactions the company received a total of an additional $ 13.2 million in the beginning of 2021. the company 's negative operating cash flow for the full year ended december 31 , 2020 , was $ 12.6 million . the company has sufficient funds to support its operation for more than 12

